Top

Published in:

01-03-2006 | Original Article

Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines

Authors: Ahmad Faried, Leri S. Faried, Hitoshi Kimura, Makoto Sohda, Masanobu Nakajima, Tatsuya Miyazaki, Hiroyuki Kato, Tatsuya Kanuma, Hiroyuki Kuwano

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2006

Abstract

Purpose: Paclitaxel is a highly effective chemotherapy agent against adenocarcinomas and squamous cell carcinomas of the esophagus. However, its precise effects in human esophageal cancer cells are not well understood. This study was designed to examine the relationship between cell-cycle phases of paclitaxel-activated checkpoints and to elucidate the molecular pathway of the effect of paclitaxel in human esophageal squamous cell carcinoma (ESCC) cell lines. Methods: The three human ESCC cell lines—TE-2, TE-13 and TE-14—were examined for their response to paclitaxel. ESCC cells were treated with various concentrations of paclitaxel for 1–3 days using MTT assay. The cell-cycle progression and apoptosis were examined by flow cytometry. DNA fragmentation assay was carried out to confirm the fragmented cells as hallmark for apoptotic cells. In additional, the expression of apoptosis-related proteins in ESCC-treated cells was then examined by Western blot analysis. Results: TE-14 cells demonstrated the highest sensitivity among all cells. G2/M cell-cycle arrest occurs prior to paclitaxel-induced apoptosis in ESCC cells. The fragmentation of chromatin was observed in drug treated TE-13 and TE-14 cells by flow cytometry and DNA ladder formation. In contrast, the measurement for TE-2 cells was more suggestive of phenotype a resistant in response to paclitaxel treatment. Western blot analysis results showed that the mitochondrial pathway might be involved in paclitaxel-induced apoptosis in ESCC cell lines. Conclusion: Differential sensitivity was observed in human ESCC cell lines in response to paclitaxel treatment. G2/M arrest occurs with a prior to paclitaxel-induced apoptosis and might be mediated by the mitochondrial (intrinsic) apoptosis pathway in human ESCC cells.

Collard JM, Otte JB, Fiasse R et al (2001) Skeletonizing en bloc esophagectomy for cancer. Ann Surg 234:25–32CrossRefPubMed

Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462–467PubMedCrossRef

Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305–313PubMed

Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327PubMedCrossRef

Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667PubMedCrossRef

Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565PubMedCrossRef

Donaldson KL, Goolsby GL, Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57:847–855PubMedCrossRef

Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS (1990) A phase II trial of taxol in metastatic melanoma. Cancer 65:2478–2481PubMedCrossRef

Holmes FA, Frye D, Theriault RL, Walters RS, Forman AD, Newton LK et al (1991) Phase II study of Taxol in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 10:60

10.

Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748–1753PubMed

11.

Stearns ME, Wang M (1992) Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 52:3776–3781PubMed

12.

Speicher LA, Barone L, Tew KD (1992) Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433–4440PubMed

13.

Tishler RB, Geard CR, Hall EJ, Schiff PB (1992) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495–3497PubMed

14.

Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086–1091PubMedCrossRef

15.

Nicholson DW (1999) Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6:1028–1042PubMedCrossRef

16.

Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309–1312CrossRefPubMed

17.

Li P, Nijhawan D, Budihardjo I et al (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479–489CrossRefPubMed

18.

Duan H, Orth K, Chinnaiyan AM et al (1996) ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem 271:16720–16724PubMedCrossRef

19.

Casciola-Rosen L, Nicholson DW, Chong T et al (1996) Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med 183:1957–1964CrossRefPubMed

20.

Silke J, Ekert PG, Day CL et al (2001) Direct inhibition of caspase 3 is dispensable for the anti-apoptotic activity of XIAP. EMBO J 20:3114–3123CrossRefPubMed

21.

Silke J, Hawkins CJ, Ekert PG et al (2002) The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase-3 and caspase-9 interacting sites. J Cell Biol 157:115–124PubMedCrossRef

22.

Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S (1999) Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. EMBO J 18:2040–2048CrossRefPubMed

23.

Xanthoudakis S, Roy S, Rasper D et al (1999) Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis. EMBO J 18:2049–2056PubMedCrossRef

24.

Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T (1993) Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 119:441–449PubMedCrossRef

25.

McGuire WP, Blessing JA, Moore D et al (1996) Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 14:792–795PubMed

26.

Untch M, Untch A, Sevin BU et al (1994) Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 5:24–30PubMedCrossRef

27.

Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271–279CrossRefPubMed

28.

Fan W, Schandl CA, Cheng L, Norris JS, Willingham MC (1996) Glucocorticoids modulate taxol cytotoxicity in human solid tumor cells. Cell Pharm 3:343–348

29.

Liebmann JE, Hahn SM, Cook JA et al (1993) Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res 53:2066–2070PubMed

30.

Chang YF, Li LL, Wu CW et al (1996) Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77:14–18CrossRefPubMed

31.

Vaux DL, Korsmeyer SJ (1999) Cell death in development. Cell 96:245–254CrossRefPubMed

32.

Shibata Y, Haruki N, Kuwabara Y et al (2002) Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 23:1695–1699PubMedCrossRef

33.

Susin SA, Zamzami N, Kroemer G (1998) Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1366:151–165PubMedCrossRef

34.

Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6:513–519PubMedCrossRef

35.

Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES (2000) Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol 2:476–483PubMedCrossRef

36.

Jiang J, Ballinger CA, Wu Y et al (2001) CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 276:42938–42944PubMedCrossRef

37.

Nomura T, Mimata H, Takeuchi Y et al (2003) The X-linked inhibitor of apoptosis protein inhibits taxol-induced apoptosis in LNCap cells. Urol Res 31:37–44PubMed

38.

Deveraux QL, Takahashi R, Salvesen GS, Reed JC (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300–304CrossRefPubMed

39.

Faried A, Sohda M, Nakajima T et al (2004) Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human esophageal squamous cell carcinoma. Eur J Cancer 40:2804–2811PubMedCrossRef

Title: Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines
Authors: Ahmad Faried
Leri S. Faried
Hitoshi Kimura
Makoto Sohda
Masanobu Nakajima
Tatsuya Miyazaki
Hiroyuki Kato
Tatsuya Kanuma
Hiroyuki Kuwano
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0038-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2006

Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1)

shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity

Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro

Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations

p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1

Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer